Clinical applications of granulocyte-colony stimulating factor.
Granulocyte colony stimulating factor (G-CSF) is a naturally occurring potent neutrophil growth factor. Recombinant human G-CSF has been developed by pharmaceutical companies, and since the late 1980's, multiple clinical trials have explored its efficacy in a variety of medical conditions. These include various inherited and acquired neutropenia, as well as mobilization of hematopoietic stem cells and progenitors for transplantation. Interestingly, in several type of inherited neutropenia where no randomized controlled studies have ever been conducted, its chronic use is considered critical for survival and deemed a standard of care. Unfortunately, it the settings of cancer treatment-related neutropenia and post hematopoietic stem cell transplantation, controversy still prevails whether universal usage of drug is cost effective despite innumerous randomized clinical trials. This review will focus on the clinical applications of G-CSF in the setting of inherited and acquired bone marrow failure, cancer treatment-related neutropenia and hematopoietic stem cell transplantation.
Sung
Lillian
L
Division of Haematology and Oncology, Department of Paediatrics, The Hospital for Sick Children , University of Toronto, 555 University Ave. Toronto, Ontario, Canada, M5G 1X8.
Dror
Yigal
Y
D000741:Anemia, Aplastic / Q000188:drug therapy; D001855:Bone Marrow Diseases / Q000188:drug therapy; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy; D009503:Neutropenia / Q000188:drug therapy; D013577:Syndrome
D016179:Granulocyte Colony-Stimulating Factor